Glaucoma medications go the distance

Article

Dorzolamide/timolol fixed combinations (DTFC) and latanoprost achieve consistent 24-hour intraocular pressure (IOP) control and obtain a significant increase in 24-hour diastolic ocular perfusion pressure over a six-month treatment period, according to Anastasios Konstas from the AHEPA Hospital, Thessaloniki, Greece.

Dorzolamide/timolol fixed combinations (DTFC) and latanoprost achieve consistent 24-hour intraocular pressure (IOP) control and obtain a significant increase in 24-hour diastolic ocular perfusion pressure over a six-month treatment period, according to Anastasios Konstas from the AHEPA Hospital, Thessaloniki, Greece.

Fifty-three patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) with an average 24-hour IOP of 25.2±2.3 mmHg were enrolled to take part in a prospective, single-masked, crossover study.

At six-months, the 24-hour IOP for those in the DTFC group was 18.2±1.9 mmHg and 18.3±1.9 mmHg for those in the latanoprost group. However, DTFC demonstrated superior IOP reduction at 10:00 hours (-0.8 mmHg, p=0.01) and at 22:00 hours (-1.1 mmHg, p<0.0001).

These results demonstrated that DTFC and latanoprost remain effective 24-hour treatments for glaucoma, even after six-months' intensive treatment.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Andreas Pollreisz, MD, discusses widefield OCT-A and fluorescence angiography at the 2025 European Society of Retina Specialists EURETINA meeting
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
© 2025 MJH Life Sciences

All rights reserved.